INO

Inovio Pharmaceuticals, Inc. (INO) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

INO’s environmental profile is constrained by a capital-light, R&D-driven model, which typically lowers direct emissions exposure versus manufacturing-heavy biotech peers.

The provided metrics show no disclosed R&D intensity or emissions data, limiting evidence of superior environmental management relative to peers with more transparent sustainability reporting.

Absence of material debt pressure can support longer-dated environmental investment capacity, but this advantage is modest versus peers with similarly low operating leverage.

No Tier 1 filing evidence was provided for waste, energy, or climate targets, so environmental positioning appears broadly average rather than differentiated versus peers.

Social

Score:

INO’s social profile is supported by a research-oriented operating model, which generally reduces workforce safety and community-impact risks versus lab- and plant-intensive peers.

The absence of disclosed stock-based compensation intensity in the provided metrics limits assessment of employee dilution pressures, which are more visible at peer companies with heavier equity use.

No filing-based evidence was provided on clinical-trial ethics, patient access, or product safety governance, leaving key biotech social factors unverified versus peers.

Limited leverage can reduce restructuring pressure on employees and stakeholders, but this is a secondary advantage relative to peers with stronger disclosed human-capital practices.

Governance

Score:

INO’s leverage metrics indicate manageable balance-sheet risk, which supports governance stability relative to more indebted peers facing tighter creditor oversight.

The provided data show zero stock-based compensation to revenue, but without filing evidence this cannot confirm stronger alignment or lower dilution than peers.

No Tier 1 disclosure was provided on board independence, executive incentives, or shareholder rights, so governance quality cannot be distinguished from peer norms.

Overall governance appears average because the available metrics suggest financial discipline, yet the absence of verifiable disclosure prevents a stronger relative assessment.

Overall Score

Score:

INO appears broadly average versus peers on ESG because its low-operating-intensity model and manageable leverage are offset by limited disclosed sustainability and governance evidence.

Score Driver: Limited Verifiable ESG Disclosure Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Inovio Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →